Judgment will ensure no ever-greening of patents: Y K Sapru

Interview with Founder chairman of Cancer Patients Aid Association

Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients. Edited excerpts: What does a judgment in CPAA's favour mean for patients across the country? The Supreme Court's judgment on the Glivec case is a landmark one. This may form the basis for decisions in all ...